Geneos Therapeutics

Geneos Therapeutics is a clinical-stage biotherapeutics company in Plymouth Meeting / Philadelphia, Pennsylvania, building DNA-based personalized immunotherapies for cancer. Its proprietary GT-EPIC platform reads a patient's own tumor mutations and manufactures a custom DNA plasmid vaccine encoding up to 40 of that patient's unique neoantigens, delivered intradermally with an IL-12 cytokine adjuvant and electroporation. In 2024 the company published Phase 1/2 GT-30 data in Nature Medicine showing its vaccine plus pembrolizumab generated new neoantigen-specific T cells and clinical responses in advanced liver cancer - billed as the first definitive demonstration of a personalized cancer vaccine boosting response to anti-PD-1 therapy.